A DNA Repair Pathway Polymorphism (rs25487) and Angiographically Proven Coronary Artery Patients in a Population of Southern Iran.

Q2 Medicine Cardiovascular and Hematological Agents in Medicinal Chemistry Pub Date : 2021-01-01 DOI:10.2174/1871525718666200805113813

Seyed M Hoseini, Mahdi Bijanzadeh, Seyed M Seyedian

{"title":"A DNA Repair Pathway Polymorphism (rs25487) and Angiographically Proven Coronary Artery Patients in a Population of Southern Iran.","authors":"Seyed M Hoseini, Mahdi Bijanzadeh, Seyed M Seyedian","doi":"10.2174/1871525718666200805113813","DOIUrl":null,"url":null,"abstract":"Background: Coronary Artery Disease (CAD), which is a multifactorial genetic disease, is known as one of the most common causes of death worldwide. In this regard, X-ray Repair Cross-Complementing group 1 (XRCC1), a DNA repair protein involved in Single-Strand Breaks (SSBs), and Base Excision Repair (BER) pathways have been reported to be responsible for the efficient repair of single strand breaks and damaged bases in DNA.Objectives: In the current study, we analyzed Arg399Gln (rs25487), which is one of the most common polymorphisms of XRCC1 gene that might be associated with the increased risk for CAD.Methods: This case-control study was performed to investigate the relationship between this polymorphism and CAD development. In this study, 290 patients and 216 controls were diagnosed by cardiac angiography and then screened for the above-mentioned polymorphism using Restriction Fragment Length Polymorphisms (RFLP) method.Results: The frequency of the GA genotype of XRCC1 Arg399Gln (rs25487) was significantly higher in CAD patients compared to the controls (p=0.002, OR: 1.21, 95% CI: 1.06-1.37). Moreover, its dominant mode (AA + GA) genotype had a 1.851-fold increase in the risk of CAD (p = 0.005).Conclusion: Our findings demonstrated that Arg399Gln polymorphism of XRCC1 (rs25487) has a significant relationship with CAD and also plays a probable predisposing role in that. Our results support the role of DNA damages and the malfunctions of DNA repair system in the patients with CAD.","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"19 1","pages":"76-82"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular and Hematological Agents in Medicinal Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871525718666200805113813","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

Abstract

Background: Coronary Artery Disease (CAD), which is a multifactorial genetic disease, is known as one of the most common causes of death worldwide. In this regard, X-ray Repair Cross-Complementing group 1 (XRCC1), a DNA repair protein involved in Single-Strand Breaks (SSBs), and Base Excision Repair (BER) pathways have been reported to be responsible for the efficient repair of single strand breaks and damaged bases in DNA.

Objectives: In the current study, we analyzed Arg399Gln (rs25487), which is one of the most common polymorphisms of XRCC1 gene that might be associated with the increased risk for CAD.

Methods: This case-control study was performed to investigate the relationship between this polymorphism and CAD development. In this study, 290 patients and 216 controls were diagnosed by cardiac angiography and then screened for the above-mentioned polymorphism using Restriction Fragment Length Polymorphisms (RFLP) method.

Results: The frequency of the GA genotype of XRCC1 Arg399Gln (rs25487) was significantly higher in CAD patients compared to the controls (p=0.002, OR: 1.21, 95% CI: 1.06-1.37). Moreover, its dominant mode (AA + GA) genotype had a 1.851-fold increase in the risk of CAD (p = 0.005).

Conclusion: Our findings demonstrated that Arg399Gln polymorphism of XRCC1 (rs25487) has a significant relationship with CAD and also plays a probable predisposing role in that. Our results support the role of DNA damages and the malfunctions of DNA repair system in the patients with CAD.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

伊朗南部人群中DNA修复通路多态性(rs25487)和血管造影证实的冠状动脉患者

背景:冠状动脉疾病(CAD)是一种多因素遗传性疾病，是世界上最常见的死亡原因之一。在这方面，x射线修复交叉互补组1 (XRCC1)是一种参与单链断裂(SSBs)和碱基切除修复(BER)途径的DNA修复蛋白，据报道，它负责DNA单链断裂和受损碱基的有效修复。目的:在本研究中，我们分析了Arg399Gln (rs25487)，这是XRCC1基因最常见的多态性之一，可能与CAD风险增加有关。方法:采用病例对照研究，探讨该多态性与CAD发展的关系。在本研究中，290例患者和216例对照者通过心脏血管造影诊断，然后使用限制性片段长度多态性(RFLP)方法筛选上述多态性。结果:XRCC1 Arg399Gln (rs25487) GA基因型在CAD患者中的出现频率明显高于对照组(p=0.002, OR: 1.21, 95% CI: 1.06-1.37)。其优势模式(AA + GA)基因型的冠心病风险增加1.851倍(p = 0.005)。结论:我们的研究结果表明，XRCC1 (rs25487)的Arg399Gln多态性与CAD有显著关系，并可能在CAD中起易感作用。我们的研究结果支持DNA损伤和DNA修复系统故障在冠心病患者中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cardiovascular and Hematological Agents in Medicinal Chemistry Medicine-Cardiology and Cardiovascular Medicine

CiteScore

2.70

自引率

0.00%

发文量

期刊介绍： Cardiovascular & Hematological Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of new Cardiovascular & Hematological Agents. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in Cardiovascular & Hematological medicinal chemistry. Cardiovascular & Hematological Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in cardiovascular & hematological drug discovery.